Eli Lilly and Co Q4 2020 Earnings Call Transcript

The following is excerpted from the question-and-answer section of the transcript.

Question: Gregory B. Gilbert - Truist Securities, Inc., Research Division - Analyst : On the COVID antibodies, Dave, I realize the latest data is quite fresh. But to the extent you're worried that there could be a disconnect between the power of the data and the speed of uptake, is there anything that Lilly plans to do proactively to help move this along? I was intrigued by your comments on the prior call about some well-known hospitals being slower than other hospitals to get trained and ready. And I think that was even from before this latest data set. And then maybe for Josh, on that call, it sounded like the upper limit of $2 billion in your guidance is not necessarily set in stone if demand picks up. What's the practical limitation from a manufacturing standpoint as it relates to 2021 for the antibodies?

Question: Kerry Ann Holford - Joh. Berenberg, Gossler & Co. KG, Research Division - Analyst : Just a couple left from me, please. Firstly, on Prevail. I wonder if you can talk a little more about this decision to acquire here. What attracted you to this particular gene therapy platform versus others? And when might we see the data readout for the lead assets? And indeed, when might we see these potentially come to market? And then my second question is just more housekeeping in nature. You talked about a stocking benefit in Q4. I think it was $120 million. Could you detail which drugs that impacted primarily and whether you'd expect an unwind into the next quarter?